Press release
Investigation announced for Investors in NYSE: SQZ shares over possible Wrongdoing at SQZ Biotechnologies Company
An investigation on behalf of investors in SQZ Biotechnologies Company (NYSE: SQZ) shares over potential wrongdoing.
Investors who purchased shares of SQZ Biotechnologies Company (NYSE: SQZ) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain SQZ Biotechnologies directors breached their fiduciary duties and caused damage to the company and its shareholders.
Watertown, MA based SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. SQZ Biotechnologies Company reported that its annual Total Revenue rose from $20.99 million in 2020 to $27.09 million in 2021, and that its Net Loss increased from $50.52 million in 2020 to $68.74 million in 2021.
On or around October 29, 2022, SQZ Biotechnologies Company conducted its initial public offering ("IPO"), selling 4,411,765 shares priced at $16.00 per share.
Then, on December 1, 2022, SQZ Biotechnologies Company issued a press release "announc[ing] that Armon Sharei, PhD, Chief Executive Officer at SQZ Biotechnologies, will step down from his role as CEO and the Board of Directors, effective immediately," and that the Company will reduce its workforce by roughly 60% as it "pause[s] its APC, Activating Antigen Carrier (AAC) and Tolerizing Antigen Carrier (TAC) programs."
Shares of SQZ Biotechnologies Company (NYSE: SQZ) declined to as low as $1.41 per share on December 5, 2022.
Those who purchased shares of SQZ Biotechnologies Company (NYSE: SQZ) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in NYSE: SQZ shares over possible Wrongdoing at SQZ Biotechnologies Company here
News-ID: 2936970 • Views: …
More Releases from Shareholders Foundation
Deadline on June 10th coming up in Lawsuit for Investors in shares of Ocugen, In …
A deadline is coming up on June 10, 2024 in the lawsuit filed for certain investors of Ocugen, Inc. (NASDAQ: OCGN) over alleged securities laws violations by Ocugen, Inc.
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN ) have certain options and there are strict and short deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to…
Investigation announced for Investors in FMC Corporation (NYSE: FMC) over potent …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of FMC Corporation.
Investors who are current long term investors in FMC Corporation (NYSE: FMC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: FMC stocks follows a lawsuit filed against FMC Corporation over…
Investigation announced for Long-Term Investors who lost money with Advance Auto …
An investigation was announced for long-term investors in shares of Advance Auto Parts, Inc. (NYSE: AAP) concerning potential breaches of fiduciary duties by certain directors of Advance Auto Parts, Inc.
Investors who are current long term investors in Advance Auto Parts, Inc. (NYSE: AAP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
Investigation announced for Investors in Treace Medical Concepts, Inc. (NASDAQ: …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Treace Medical Concepts, Inc.
Investors who purchased shares of Treace Medical Concepts, Inc. (NASDAQ: TMCI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Treace Medical Concepts, Inc. directors breached their fiduciary duties and caused damage to the company and its…
More Releases for SQZ
Vascular Endothelial Growth Factor (VEGF) Market is projected to expand at a CAG …
Growing significance of genomics and proteomics has been contributing to the growth of the global vascular endothelial growth factor (VEGF) market. The market was valued at US$ 195.4 Mn at the end of 2021 and is projected to expand at a CAGR of 10.7% over the forecast period (2022-2032), according to Persistence Market Research.
Tumor cells, keratinocytes, platelets, renal mesangial cells, and macrophages are among the cells that produce VEGF. VEGF's…
Cosmetic Peptide Synthesis Market is projected to expand at a CAGR of 10.7% over …
Growing significance of genomics and proteomics has been contributing to the growth of the global vascular endothelial growth factor (VEGF) market. The market was valued at US$ 195.4 Mn at the end of 2021 and is projected to expand at a CAGR of 10.7% over the forecast period (2022-2032), according to Persistence Market Research.
Tumor cells, keratinocytes, platelets, renal mesangial cells, and macrophages are among the cells that produce VEGF. VEGF's…
Gene Therapy Clinical Trials Show Promising Future Opportunity With More Than 10 …
Nearly half a century ago, the concept of tinkering the genes and to visualize it in the genotype or phenotype of the patient was not less than a dream but the constant research and efforts by the researchers have made the concept an established protocol in the medical world. The process of gene therapy has made it possible to precisely manipulate the genetic material of an individual and bring the…
Global Gene Therapy Market Size Sales To Surpass USD 8 Billion By 2026
" Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlights:
o Global Gene Therapy market Opportunity: > USD 8 Billion
o Global Gene Therapy Pipeline:: > 1000 In Trials
o Commercially Available Gene Therapies: 11
o US & Europe Are Key Markets
Download Report: http://pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026
1. Introduction to Gene Therapy
1.1 Gene Therapy: An Overview
1.2 History of Development
2. Gene Therapy & its Impact on Genetic Alterations
2.1 Gene Therapy as a Mastermind of Genetic Revolution
…
